Andre E Nel

US Patent:

20080295187, Nov 27, 2008

Filed:

Dec 6, 2006

Appl. No.:

12/095902

Inventors:

Andre E. Nel - Sherman Oaks CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A01K 67/027
C12Q 1/02
C12Q 1/48
C12Q 1/28
C12Q 1/68

US Classification:

800 3, 435 29, 435 15, 435 28, 435 6

Abstract:

A method based is provided for determining the toxicity of engineered nanomaterials (NM). The method comprises in vitro assays for oxidative stress associated with exposure to engineered NM, which comprise assays for: reactive oxygen species production; phase II and glutathione antioxidant molecule expression; activation of MAP and NF-kappa B kinase signaling cascades; production of cytokines, chemokines and adhesion molecules; mitochondrial perturbation and apoptosis; and cellular uptake and subcellular localization of the NM. The method further comprises in vivo assays for oxidative stress in subjects exposed to NM.

US Patent:

20100255103, Oct 7, 2010

Filed:

Dec 8, 2008

Appl. No.:

12/746375

Inventors:

Monty Liong - Los Angeles CA, US
Jie Lu - Los Angeles CA, US
Fuyuhiko Tamanoi - Los Angeles CA, US
Jeffrey I. Zink - Sherman Oaks CA, US
Andre Nel - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 9/14
A61K 31/4375
A61K 31/337
A61K 31/05
A61K 31/7048
A61K 31/17
A61P 35/00

US Classification:

424489, 514283, 514449, 514733, 514 27, 514589, 977773, 977906

Abstract:

A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of said plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.

US Patent:

20100284924, Nov 11, 2010

Filed:

Jan 23, 2009

Appl. No.:

12/812359

Inventors:

Jeffrey I. Zink - Sherman Oaks CA, US
Fuyuhiko Tamanoi - Los Angeles CA, US
Eunshil Choi - Los Angeles CA, US
Sarah Angelos - Corvallis OR, US
Sanaz Kabehie - Los Angeles CA, US
Andre Nel - Sherman Oaks CA, US
Jie Lu - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 9/14
B32B 5/00
A61K 8/02
A61K 49/00
A61P 43/00
A61P 35/00
A61Q 90/00

US Classification:

424 91, 428402, 424489, 424401

Abstract:

A nanodevice has a containment vessel defining a storage chamber therein and defining at least one port to provide transfer of molecules to or from the storage chamber, and a plurality of impellers attached to the containment vessel. The plurality of impellers are of a structure and are arranged to substantially block molecules from entering and exiting the storage chamber of the containment vessel when the impellers are static and are operable to impart motion to the molecules to cause the molecules to at least one of enter into or exit from the storage chamber of the containment vessel.

US Patent:

20100310465, Dec 9, 2010

Filed:

Jul 22, 2010

Appl. No.:

12/841331

Inventors:

Jeffrey I. Zink - Sherman Oaks CA, US
Jie Lu - Los Angeles CA, US
Fuyuhiko Tamanoi - Los Angeles CA, US
Andre Nel - Sherman Oaks CA, US
Sarah Angelos - Corvallis OR, US
Fraser Stoddart - Evanston IL, US
Qiaolin Chen - Los Angeles CA, US
Tian Xia - Los Angeles CA, US
Kaushik Patel - Bayside WI, US
William Dichtel - Ithaca NY, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 9/14
A61K 31/352
A61P 27/02
A61P 39/06
A61P 29/00
A61P 37/06
A61P 35/00
A61P 25/08
A61P 31/12
A61P 9/12
A61P 7/02
B01J 19/00
A61K 49/00

US Classification:

424 91, 514454, 424489, 422105, 977724

Abstract:

A nanodevice has a containment vessel defining a storage chamber therein and defining at least one port to provide access to and from said storage chamber, and a stopper assembly attached to the containment vessel. The stopper assembly has a blocking unit arranged proximate the at least one port and has a structure suitable to substantially prevent material after being loaded into the storage chamber from being released while the blocking unit is arranged in a blocking configuration. The stopper assembly is responsive to the presence of a predetermined stimulus such that the blocking unit is released in the presence of the predetermined stimulus to allow the material to be released from the storage chamber. The predetermined stimulus is a predetermined catalytic activity that is suitable to at least one of cleave, hydrolyze, oxidize, or reduce a portion of the stopper assembly, and the nanodevice has a maximum dimension of about 1 μm.

US Patent:

20120034266, Feb 9, 2012

Filed:

Mar 3, 2009

Appl. No.:

12/921113

Inventors:

Andre E. Nel - Sherman Oaks CA, US

International Classification:

A61K 39/145
A61K 39/39
A61P 31/16
C07C 331/20
A61P 37/04
A61P 31/04
A61K 31/26
A61K 39/09

US Classification:

4242091, 4242781, 4241841, 4242441, 558 17

Abstract:

The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.

US Patent:

20120207795, Aug 16, 2012

Filed:

Mar 23, 2012

Appl. No.:

13/428830

Inventors:

Jeffrey I. Zink - Sherman Oaks CA, US
Andre E. Nel - Sherman Oaks CA, US
Tian Xia - Los Angeles CA, US
Zhaoxia Ji - Los Angeles CA, US
Huan Meng - Torrance CA, US
Zongxi Li - Los Angeles CA, US
Monty Liong - Charlestown MA, US
Min Xue - Los Angeles CA, US
Derrick Y. Tarn - Irvine CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 31/713
A61P 35/00
A61K 9/00
B32B 3/26
C12N 5/071
B82Y 5/00

US Classification:

424400, 428402, 514 44 A, 514 44 R, 435375, 977773, 977915

Abstract:

A submicron structure having a silica body defining a plurality of pores is described. The submicron body may be spherical or non-spherical, and may include a cationic polymer or co-polymer on the surface of said silica body. The submicron structure may further include an oligonucleotide and be used to deliver the oligonucleotide to a cell. The submicron structure may further include a therapeutic agent and be used to deliver the therapeutic agent to a cell. An oligonucleotide and therapeutic agent may be used together. For example, when the oligonucleotide is an siRNA, the composition may be used to decrease cellular resistance to the therapeutic agent by decreasing translation of a resistance gene.

US Patent:

20130344106, Dec 26, 2013

Filed:

May 31, 2013

Appl. No.:

13/907799

Inventors:

ANDRE E. NEL - SHERMAN OAKS CA, US

International Classification:

A61K 39/39

US Classification:

4242091, 4242781, 4242241, 4242261, 4242271, 4242281, 4242041, 4242121, 4242111, 4242191, 4242451, 4242401, 4242391, 4242301, 4242151, 4242501

Abstract:

The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.

US Patent:

20200197534, Jun 25, 2020

Filed:

Nov 18, 2019

Appl. No.:

16/687368

Inventors:

- Oakland CA, US
Huan Meng - Los Angeles CA, US
Andre E. Nel - Sherman Oaks CA, US

International Classification:

A61K 47/69
A61K 47/55
A61K 47/54

Abstract:

In certain embodiments a platform technology for the facilitating immune therapy in the treatment of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor-prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB)-coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site.